Q4 2022 EPS Estimates for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Lowered by Jefferies Financial Group

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTKGet Rating) – Equities research analysts at Jefferies Financial Group lowered their Q4 2022 EPS estimates for Paratek Pharmaceuticals in a research note issued to investors on Wednesday, May 4th. Jefferies Financial Group analyst S. Jeong now forecasts that the specialty pharmaceutical company will post earnings per share of $0.23 for the quarter, down from their previous forecast of $0.25. Jefferies Financial Group also issued estimates for Paratek Pharmaceuticals’ FY2026 earnings at $1.03 EPS.

Other analysts have also issued reports about the stock. StockNews.com upgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. BTIG Research cut their target price on shares of Paratek Pharmaceuticals from $34.00 to $30.00 in a research report on Monday, April 11th. Zacks Investment Research lowered shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, March 18th. HC Wainwright cut their target price on shares of Paratek Pharmaceuticals from $27.00 to $22.00 and set a “buy” rating for the company in a research report on Thursday, March 17th. Finally, WBB Securities upgraded shares of Paratek Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $11.00 target price for the company in a research report on Thursday, February 10th.

Shares of PRTK stock opened at $2.16 on Friday. The company has a 50 day moving average price of $2.87 and a 200-day moving average price of $3.89. Paratek Pharmaceuticals has a 52 week low of $2.03 and a 52 week high of $11.23.

Paratek Pharmaceuticals (NASDAQ:PRTKGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The specialty pharmaceutical company reported ($0.35) EPS for the quarter, hitting analysts’ consensus estimates of ($0.35). During the same quarter in the prior year, the business earned ($0.39) earnings per share.

Large investors have recently modified their holdings of the business. BNP Paribas Arbitrage SA lifted its holdings in Paratek Pharmaceuticals by 378.5% during the third quarter. BNP Paribas Arbitrage SA now owns 7,967 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 6,302 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Paratek Pharmaceuticals in the fourth quarter worth $56,000. Invesco Ltd. purchased a new position in shares of Paratek Pharmaceuticals in the second quarter worth $99,000. Citigroup Inc. lifted its holdings in shares of Paratek Pharmaceuticals by 70.7% in the fourth quarter. Citigroup Inc. now owns 14,664 shares of the specialty pharmaceutical company’s stock worth $66,000 after buying an additional 6,075 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Paratek Pharmaceuticals in the fourth quarter worth $76,000. 59.46% of the stock is currently owned by institutional investors and hedge funds.

Paratek Pharmaceuticals Company Profile (Get Rating)

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.

See Also

Earnings History and Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.